Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

@article{Fleseriu2012MifepristoneAG,
  title={Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.},
  author={Maria Fleseriu and Beverly M. K. Biller and James W. Findling and Mark E Molitch and David E. Schteingart and Coleman Gross},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2012},
  volume={97 6},
  pages={2039-49}
}
CONTEXT Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations. OBJECTIVE Our objective was to evaluate the safety and efficacy of mifepristone, a glucocorticoid receptor antagonist, in endogenous CS. DESIGN AND SETTING We conducted a 24-wk multicenter, open-label trial after failed multimodality therapy at 14 U.S. academic medical centers and three private research centers. PARTICIPANTS… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
112 Extracted Citations
42 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 112 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…